 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: Byfavo® | CNS-7056 | CNS7056
                                 remimazolam is an approved drug (FDA (2020), EMA (2021)) Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Remimazolam is a benzodiazepine type compound, that was developed as an ultra-short-acting sedative/anesthetic [3-4]. This compound combines the actions of the opioid analgesic remifentanil with that of the currently used sedative midazolam (GABAA receptor modulator). Remimazolam is proposed as a safer alternative to the current standard of care.
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| Classification  | |
| Compound class | Synthetic organic | 
| Approved drug? | Yes. EU EMA (2021) | US FDA (2020) | 
| IUPAC Name  | 
| methyl 3-[(4S)-8-bromo-2-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 9232 | remimazolam | 
| Synonyms  | 
| Byfavo® | CNS-7056 | CNS7056 | 
| Database Links  | |
| CAS Registry No. | 308242-62-8 | 
| GtoPdb PubChem SID | 252166652 | 
| PubChem CID | 9824461 | 
| Search Google for chemical match using the InChIKey | GHUYIIGPWBMOGY-KRWDZBQOSA-N | 
| Search Google for chemicals with the same backbone | GHUYIIGPWBMOGY | 
| Search PubMed clinical trials | remimazolam | 
| Search PubMed titles | remimazolam | 
| Search PubMed titles/abstracts | remimazolam | 
| UniChem Compound Search for chemical match using the InChIKey | GHUYIIGPWBMOGY-KRWDZBQOSA-N | 
| UniChem Connectivity Search for chemical match using the InChIKey | GHUYIIGPWBMOGY-KRWDZBQOSA-N |